GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced today that it has entered into a warrant inducement agreement with an existing institutional investor. The agreement provides for the immediate exercise of existing warrants to purchase up to 5,697,628 shares of common stock at an exercise price of $0.64 per share, resulting in gross cash proceeds of approximately $3,646,482 before deducting financial advisor fees and other transaction expenses.
The company stated that it intends to use the net proceeds from the offering for working capital and other general corporate purposes. In consideration for the immediate exercise of the existing warrants, the investor will receive, in a private placement, new unregistered warrants to purchase up to 11,395,256 shares of common stock. These new warrants will have the same exercise price of $0.64, will become exercisable on the date that shareholder approval for the issuance of the underlying shares is obtained, and will expire five years following that approval date.
The closing of the warrant inducement transaction is expected to occur on or about August 27, 2026, subject to customary closing conditions. The private placement will be conducted in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, meaning the securities issued cannot be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption.
This financial move comes as GeoVax advances its key programs. The company’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. GEO-MVA is progressing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. This trial aims to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities.
The warrant inducement transaction is a strategic step to secure additional capital for the company’s ongoing operations and development activities. By providing an incentive for the immediate exercise of existing warrants, GeoVax can bolster its working capital position without incurring additional debt or diluting existing shareholders beyond the issuance of new warrants.
Investors and stakeholders will be watching closely as GeoVax moves forward with its clinical programs and seeks to bring its vaccine and immunotherapy candidates to market. The company’s ability to secure funding through such transactions is crucial for its continued progress and for meeting its development milestones.
